Works matching Epidermal growth factor


Results: 5000
    1
    2
    3
    4
    5
    6
    7
    8
    9

    A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor‐Induced Skin Toxicities.

    Published in:
    Oncologist, 2020, v. 25, n. 1, p. e186, doi. 10.1634/theoncologist.2019-0221
    By:
    • Kim, Young Saing;
    • Ji, Jun Ho;
    • Oh, Sung Yong;
    • Lee, Suee;
    • Huh, Seok Jae;
    • Lee, Ji Hyun;
    • Song, Ki‐Hoon;
    • Son, Choon Hee;
    • Roh, Mee Sook;
    • Lee, Gyeong Won;
    • Lee, Jeeyun;
    • Kim, Seung Tae;
    • Kim, Chan Kyu;
    • Jang, Joung Soon;
    • Hwang, In Gyu;
    • Ahn, Hee Kyung;
    • Park, Lee Chun;
    • Oh, So Yeon;
    • Kim, Seong‐Geun;
    • Lee, Sang‐Cheol
    Publication type:
    Article
    10
    11
    12
    13
    15
    16
    17
    18
    19
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33

    Nodal positivity and systemic therapy among patients with clinical T1–T2N0 human epidermal growth factor receptor‐positive breast cancer: Results from two international cohorts.

    Published in:
    Cancer (0008543X), 2023, v. 129, n. 12, p. 1836, doi. 10.1002/cncr.34750
    By:
    • Weiss, Anna;
    • Martínez‐Sáez, Olga;
    • Waks, Adrienne G.;
    • Laws, Alison;
    • McGrath, Monica;
    • Tarantino, Paolo;
    • Portnow, Leah;
    • Winer, Eric;
    • Rey, María;
    • Tapia, Marta;
    • Prat, Aleix;
    • Partridge, Ann H.;
    • Tolaney, Sara M.;
    • Cejalvo, Juan M.;
    • Mittendorf, Elizabeth A.;
    • King, Tari A.
    Publication type:
    Article
    34
    35

    Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208).

    Published in:
    JNCI: Journal of the National Cancer Institute, 2024, v. 116, n. 9, p. 1487, doi. 10.1093/jnci/djae114
    By:
    • Hochster, Howard S;
    • Catalano, Paul;
    • Weitz, Michelle;
    • Mitchell, Edith P;
    • Cohen, Deirdre;
    • O'Dwyer, Peter J;
    • Faller, Bryan A;
    • Kortmansky, Jeremy S;
    • O'Hara, Mark H;
    • Kricher, Sheetal M;
    • Lacy, Jill;
    • Lenz, Heinz-Josef;
    • Verma, Udit;
    • Benson, Al B
    Publication type:
    Article
    36
    37
    38
    39
    40
    41
    42
    43
    45
    46
    47

    Olmutinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study.

    Published in:
    2021
    By:
    • Park, Keunchil;
    • Jӓnne, Pasi A.;
    • Kim, Dong‐Wan;
    • Han, Ji‐Youn;
    • Wu, Ming‐Fang;
    • Lee, Jong‐Seok;
    • Kang, Jin‐Hyoung;
    • Lee, Dae Ho;
    • Cho, Byoung Chul;
    • Yu, Chong‐Jen;
    • Pang, Yong Kek;
    • Felip, Enriqueta;
    • Kim, Hyunjin;
    • Baek, Eunhye;
    • Noh, Young Su;
    • Kim, Dong-Wan;
    • Han, Ji-Youn;
    • Wu, Ming-Fang;
    • Lee, Jong-Seok;
    • Kang, Jin-Hyoung
    Publication type:
    journal article
    48
    49
    50